Impact of *Achromobacter xylosoxidans* isolation on the respiratory function of adult patients with cystic fibrosis

Macha Tetart¹, Frederic Wallet², Maeva Kyheng³, Sylvie Leroy⁴, Thierry Perez¹, Olivier Le Rouzic ¹, Benoit Wallaert¹ and Anne Prevotat¹

Affiliations: ¹CHU Lille, Adult Cystic Fibrosis Center, Lille, France. ²CHU Lille, Bacteriology Laboratory, Lille, France. ³Univ. Lille, CHU Lille, EA 2694 – Santé publique: épidémiologie et qualité des soins, Lille, France. ⁴Nice University Hospital, Adult Cystic Fibrosis Center, Nice, France.

Correspondence: Macha Tetart, CHU Lille, Adult Cystic Fibrosis Center, Boulevard Professeur Leclercq, 59 000 Lille, France. E-mail: macha_tetart@hotmail.com

ABSTRACT

Background: The prevalence of *Achromobacter xylosoxidans* lung isolation in cystic fibrosis (CF) patients has increased, but the impact on lung function is controversial. The aim of this study was to evaluate the long-term effects of *A. xylosoxidans* isolation on respiratory function of adult patients with CF in the first 3 years after identification of *A. xylosoxidans* isolation.

Methods: This was a case-control retrospective study performed at a single CF centre in Lille, France. Data for 36 patients with CF who had at least one sputum culture positive for *A. xylosoxidans* (Ax+) were evaluated and compared with control CF patients uninfected by *A. xylosoxidans* (Ax-). Respiratory function and exacerbation frequency were evaluated between 1 year prior to and 3 years after *A. xylosoxidans* isolation.

Results: Compared with the Ax- group, the Ax+ group had a lower forced expiratory volume in 1 s (FEV₁) at baseline (median (interquartile range): 55.2% (50.6–59.8%) versus 73.8% (67.2–80.4%); p=0.005), a greater decline in FEV₁ (±SE) in the first year after *A. xylosoxidans* identification (–153.6±16.1 mL·year^{–1} versus –63.8±18.5 mL·year^{–1}; p=0.0003), and more exacerbations in the first 3 years after *A. xylosoxidans* identification (9 (7–12) versus 7 (5–10); p=0.03). Ax+ patients co-colonised with *Pseudomonas aeruginosa* (n=27, 75%) had a greater FEV₁ decline (p=0.003) and more exacerbations in the year after *A. xylosoxidans* identification (p=0.037) compared with patients colonised with *A. xylosoxidans* alone. Patients with chronic *A. xylosoxidans* isolation (n=23, 64%) had more exacerbations than intermittently colonised patients in the 3 years after *A. xylosoxidans* identification (p=0.012).

Conclusion: *A. xylosoxidans* isolation is associated with a decline in respiratory function in patients with CF. Chronic *A. xylosoxidans* isolation and *P. aeruginosa* co-isolation may be markers of more severe respiratory disease in Ax+ patients.

@ERSpublications

Respiratory isolation of *Achromobacter xylosoxidans* exacerbates the decline in respiratory function in CF. Chronic *A. xylosoxidans* isolation and *Pseudomonas* cocolonisation may be markers of more severe disease in *A. xylosoxidans*-positive patients. <http://bit.ly/2yJbSOS>

Cite this article as: Tetart M, Wallet F, Kyheng M, *et al.* Impact of *Achromobacter xylosoxidans* isolation on the respiratory function of adult patients with cystic fibrosis. *ERJ Open Res* 2019; 5: 00051-2019 [<https://doi.org/10.1183/23120541.00051-2019>].

Introduction

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator gene and is the most common autosomal recessive genetic disease in France [1,2]. The predominant respiratory features of CF are bronchiectasis, bacterial isolation, and recurrent infections. *Staphylococcus aureus* and *Haemophilus influenzae* are the most prevalent bacteria in the sputum of young patients with CF, whereas *Pseudomonas aeruginosa* predominates in later decades. Other opportunistic pathogens, including *Achromobacter xylosoxidans*, *Burkholderia cepacia* and *Stenotrophomonas maltophilia*, are increasingly detected in patients lungs with CF [3]. Respiratory impairment is the major cause of death in patients with CF [4], underscoring the need for a greater understanding of how bacterial isolation and co-isolation patterns, particularly the interplay between “classical” and “emerging” pathogens, influence pulmonary function in these patients.

In France, the prevalence of *A. xylosoxidans* in the sputum of patients with CF has increased from 5.6% in 2014 to 6.3% in 2016 [1]. *A. xylosoxidans* is a strict aerobic Gram-negative bacillus [5] with broad natural resistance and frequent acquired resistance to antibiotics. These features are shared with *P. aeruginosa*, which in some cases has resulted in the inadvertent misidentification of *A. xylosoxidans* as *P. aeruginosa* [6]. However, while *P. aeruginosa* is a well-characterised agent of lung disease in patients with CF, the clinical significance of *A. xylosoxidans* isolation on the decline in lung function of patients with CF remains controversial. LAMBIASE *et al.* [7] and DE BAETS *et al.* [8] did not detect differences in the rate of decline in lung function of *A. xylosoxidans*-colonised (referred to as Ax+) and uncolonised (Ax-) patients with CF. In contrast, a recent Spanish study of CF patients found that airway isolation with *Achromobacter* spp. accelerated lung function decline and increased the number of pulmonary exacerbations [9]. Thus, further studies are necessary to clarify the clinical impact of *Achromobacter* spp. isolation.

To address this knowledge gap, we performed a case-control study by comparing the respiratory function of 36 Ax+ and 36 Ax- patients with CF (controls matched for age, sex, and *P. aeruginosa* isolation status) during the year before and the first 3 years after isolation of *A. xylosoxidans*. The main study objective was to determine the longitudinal effect of *A. xylosoxidans* isolation on respiratory function and exacerbation frequency in patients with CF. Secondary objectives were to evaluate these features in Ax+ patient subgroups with or without *P. aeruginosa* co-isolation and with intermittent *versus* chronic *A. xylosoxidans* infection.

Materials and methods

Patients

Between 2011 and 2017, a total of 275 adult subjects with CF were followed at the Lille Cystic Fibrosis Centre (Centre de Ressources et de Compétences pour la Mucoviscidose) in France. The Observatory Research Protocol Evaluation Committee reviewed the study and granted permission to analyse patient data without the need for informed consent. The Institutional Review Board of the French Language Pulmonary Society (CEPRO 2012-009) approved the study. CF diagnosis criteria were sweat chloride concentration $>60 \text{ mmol}\cdot\text{L}^{-1}$, and/or genetic confirmation of two CF-associated mutations, and two clinical features consistent with CF [10]. Of the 275 patients followed over the 7-year period, data from 36 patients with and 36 patients without *A. xylosoxidans* isolation were analysed for this report. Ax+ patients were defined as having at least one Ax+ sputum sample confirmed by cytobacteriological examination between 2011 and 2017. Control subjects were individually case matched by age (± 4 years), sex and *P. aeruginosa* isolation status. Data were collected from 1 year prior to until 3 years after baseline, which was defined as the date on which *A. xylosoxidans* was first detected or, for the case-matched controls, the same age (± 4 years) as the Ax+ patients at baseline.

Measures and data collection

All patients were evaluated every 3 months, at which time they provided a sputum sample and underwent spirometry using the MICRO spirometer 5000 (Medisoftware; Sorinnes, Belgium). Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV_1) were expressed as the percentage of predicted normal values [11]. The numbers of exacerbations and antibiotic treatment courses were recorded for each year. An exacerbation was defined as a respiratory condition requiring antibiotics regardless of the type of antibiotic, the duration of treatment or the route of administration. Chronic isolation was defined as at least two Ax+ sputum samples within 6 months. Long-term antibiotic therapy (usually oral azithromycin or aerosol colimycin) was defined as treatment for ≥ 6 months. Sputum samples were analysed for *A. xylosoxidans*, *P. aeruginosa*, *B. cepacia*, non-tuberculous mycobacteria, methicillin-sensitive *S. aureus*, and methicillin-resistant *S. aureus*.

Statistical analysis

Categorical variables are expressed as number and percentage. Continuous variables are reported as median and interquartile range (IQR) or mean $\pm$ SD. Normality of continuous variables was checked graphically and by Shapiro–Wilk’s test. Baseline characteristics of the Ax+ and Ax– groups were compared using a McNemar test for categorical variables and a Wilcoxon’s signed rank test for continuous variables. Subgroups stratified by *P. aeruginosa* co-isolation and intermittent versus chronic *A. xylosoxidans* isolation were compared using the Chi-squared test (or Fisher’s exact test when expected cell frequency was <5) for categorical variables and the Mann–Whitney U-test for continuous variables. Changes in FEV₁ were compared between groups and/or subgroups using linear mixed models. Group, time, and group $\times$ time interaction were included as fixed effects and patients as a random effect in all comparisons to account for the correlation between repeated measures. For the comparisons between Ax+ and Ax– groups, we added a second random effect to account for the matched sets, and comparisons were adjusted for age. The total number of exacerbations during the first, the first 2, and 3 years after *A. xylosoxidans* isolation were compared between groups using a generalised linear mixed model (Poisson distribution, log link function) unadjusted and adjusted for age, including matched sets as a random effect.

Statistical testing was conducted at the two-tailed α -level of 0.05. Data were analysed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).

Results

Baseline characteristics

The study cohort consisted of 72 out of the 275 adult patients with CF who were followed at our centre from 2011 to 2017. On average, patients received a consultation every 3 months, at which time they provided a sputum sample and underwent spirometry. Of the 72 patients, 36 had at least one sample positive for *A. xylosoxidans*. Each *A. xylosoxidans*+ patient was matched by age (± 4 years), sex and *P. aeruginosa* isolation status to a control patient who remained *A. xylosoxidans*– throughout the 4-year study period. Baseline characteristics are reported in table 1. The median age at baseline of the *A. xylosoxidans*– group was significantly younger than that of the *A. xylosoxidans*+ group (19.5 versus 23.5 years; $p < 0.001$); this difference can likely be attributed to the criteria used for age matching (± 4 years). In both study groups, the sex ratio was balanced and 75% of patients were co-colonised with *P. aeruginosa*. *A. xylosoxidans*+ patients had a significantly lower baseline FEV₁ than the

TABLE 1 Baseline characteristics of *Achromobacter xylosoxidans*-colonised and matched uncolonised patients with cystic fibrosis

Characteristics	Control subjects (n=36)	Patients (n=36)	p-value
Female	19 (52.8)	19 (52.8)	1.00
Age years	19.5 (17.0–27.0)	23.5 (20.0–31.0)	<0.001
BMI kg·m ⁻²	20.6 (19.2–21.8)	19.5 (17.7–21.0)	0.12
Homozygous F508del	14 (41.2)	14 (41.2)	1.00
Heterozygous F508del	13 (36.1)	17 (47.2)	0.28
Pancreatic insufficiency	30 (83.3)	30 (83.3)	1.00
Diabetes	8 (22.2)	11 (30.6)	0.44
Long-term azithromycin	10 (27.8)	14 (38.9)	0.28
Transplantation during follow-up	0 (0.0)	7 (19.4)	0.011
Lumacaftor+ivacaftor treatment	7 (19.4)	6 (16.6)	NA
<i>Pseudomonas aeruginosa</i> isolation	27 (75.0)	27 (75.0)	0.56
MSSA isolation	21 (58.3)	22 (61.1)	0.82
MRSA isolation	5 (13.9)	8 (22.2)	0.37
<i>Burkholderia cepacia</i> isolation	4 (11.1)	3 (8.3)	NA
Non-tuberculous mycobacteria	2 (5.5)	4 (11.1)	NA
Allergic bronchopulmonary aspergillosis	11 (30.6)	18 (50.0)	0.071
Intravenous antibiotherapy courses in the previous year n	1.5 (0.0–5.0)	2.0 (0.0–4.0)	0.71
Long-term (>6 months) maintenance antibiotherapy in the previous year n	13 (40.6)	19 (52.8)	0.27
Exacerbations in the previous year n	2.0 (1.0–4.0)	2.0 (1.0–3.5)	0.77
FEV ₁ at baseline %	73.8 (67.2–80.4)	55.2 (50.6–59.8)	0.005
FVC at baseline %	88.1 (81.3–94.9)	76.2 (71.5–81.0)	0.22

Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; MSSA: methicillin-sensitive *Staphylococcus aureus*; MRSA: methicillin-resistant *S. aureus*; FEV₁: forced expiratory volume in 1s; FVC: forced vital capacity; NA: not analysed.

TABLE 2 Differences in respiratory function and exacerbations between patients with cystic fibrosis who had at least one sputum culture positive for *Achromobacter xylosoxidans* (Ax+) and cystic fibrosis patients uninfected by *A. xylosoxidans* (Ax-)

Characteristics	Control subjects (n=36)	Patients (n=36)	p-value
Lung function			
ΔFEV_1 %·year ⁻¹	-3.05±0.54	-5.27±0.47	0.002 [#]
ΔFEV_1 mL·year ⁻¹	-63.8±18.5	-153.6±16.1	<0.001 [#]
ΔFVC %·year ⁻¹	-2.42±0.86	-3.58±0.56	0.18
ΔFVC mL·year ⁻¹	-101.0±32.1	-160.0±21.0	0.06
Exacerbations n			
Year before baseline	1.5 [0.0–5.0]	2.0 [1.0–3.5]	0.77 [¶]
Year after baseline	0.5 [0.0–4.0]	2.0 [1.0–4.0]	0.16 [¶]
Years 1 and 2 after baseline ⁺	5.0 [4.0–6.0]	6.0 [4.0–8.0]	0.034 [¶]
Years 1–3 after baseline ⁺	7.0 [5.0–10.0]	9.0 [7.0–12.0]	0.033 [¶]

Data are presented as $\beta \pm SE$ (slope of change calculated from the baseline (time of bacterial detection)) or median (interquartile range), unless otherwise stated. FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity. [#]: Calculated from the group×time interaction term of the linear mixed model; [¶]: calculated using a generalised linear mixed model (Poisson regression model) including matched sets as a random effect; ⁺: cumulative number of exacerbations.

A. xylosoxidans— patients (median 55.2% versus 73.8%; $p=0.005$), whereas baseline FVC did not differ significantly ($p=0.22$).

Respiratory impact of *A. xylosoxidans* isolation

To assess how *A. xylosoxidans* isolation affected respiratory function, we measured the annual rate of change in FEV₁ and FVC from baseline to the end of year 3. Over this period, a total of 812 evaluations were performed (439 in the Ax+ group, 373 in the Ax- group), which corresponds to an average of 2.8 evaluations per patient per year. As shown in table 2, the Ax+ group had a larger annual decline in FEV₁ ($-153.6 \text{ mL} \cdot \text{year}^{-1}$ versus $-63.8 \text{ mL} \cdot \text{year}^{-1}$; $p<0.001$; $-5.27\% \cdot \text{year}^{-1}$ versus $-3.05\% \cdot \text{year}^{-1}$; $p=0.002$). Although a similar trend was observed for FVC, the difference between the Ax+ and Ax- groups did not reach statistical significance ($-101.0 \text{ mL} \cdot \text{year}^{-1}$ versus $-160.0 \text{ mL} \cdot \text{year}^{-1}$; $p=0.060$) (table 2). Moreover, as shown in figure 1, the ventilatory function of Ax+ patients was poorer than that of Ax- patients at baseline and declined further over the next 3 years ($p=0.02$). In contrast, FEV₁ remained stable in the Ax- patients over the same time period.

The exacerbation rate during the year before and the year after baseline were not significantly different between the Ax+ and Ax- patients (table 2). However, the cumulative number of exacerbations in the Ax+ group was significantly higher than that in the Ax- group by the end of the second year (median 6.0

FIGURE 1 Change in forced expiratory volume in 1 s (FEV₁) with time for patients with cystic fibrosis who had at least one sputum culture positive for *Achromobacter xylosoxidans* (Ax+) and cystic fibrosis patients uninfected by *A. xylosoxidans* (Ax-). Data are presented as the mean±SD of FEV₁ recorded in the preceding year.

versus 5.0; $p=0.034$) and third year (9.0 versus 7.0; $p=0.033$) after baseline (table 2). The median total number of exacerbations in the 3 years after baseline were 9 and 7 for the Ax+ and Ax− group, respectively. The same results were found when the statistical model was adjusted for age.

Respiratory impact of *P. aeruginosa* co-isolation with *A. xylosoxidans*

Next, we evaluated the baseline characteristics and decline in respiratory function of the Ax+ patients according to *P. aeruginosa* isolation status (table 3). As noted, 27 (75%) of the Ax+ group were colonised by *P. aeruginosa*, with a median time between the first detection of *P. aeruginosa* and *A. xylosoxidans* of 66 months (range: 4–288 months). The annual rate of FEV₁ decline was greater for the *A. xylosoxidans* and *P. aeruginosa* co-colonised patients than for those colonised with *A. xylosoxidans* alone ($-169.2 \text{ mL}\cdot\text{year}^{-1}$ versus $-105.4 \text{ mL}\cdot\text{year}^{-1}$; $p=0.092$; $-6.05\%\cdot\text{year}^{-1}$ versus $-2.66\%\cdot\text{year}^{-1}$; $p=0.003$). In contrast, the numbers of exacerbations in the year before baseline and in years 2 and 3 after baseline were comparable between the two groups, and a significant difference was detected only in the first year after *A. xylosoxidans* detection (Ax+ 3.0 versus Ax− 2.0; $p=0.037$) (table 3).

Comparison of respiratory function in patients with intermittent or chronic *A. xylosoxidans* isolation

Of the 36 Ax+ patients examined, 23 (63.9%) had at least two positive sputum samples within the 6 months prior to baseline and were considered to be chronically infected. The baseline characteristics and decline in respiratory function of patients with intermittent versus chronic *A. xylosoxidans* infection are shown in table 4. At baseline, chronically *A. xylosoxidans*-infected patients were significantly younger, had lower body weights and had been treated with significantly more azithromycin cycles than the intermittently infected patients. There were no significant differences between the two groups in either FEV₁ at baseline (median 58.0 versus 49.0%; $p=1.00$) or the annual rate of decline in FEV₁ in the 3 years after baseline ($-135.9 \text{ mL}\cdot\text{year}^{-1}$ versus $-157.2 \text{ mL}\cdot\text{year}^{-1}$; $p=0.062$). In contrast, the chronically infected group had a significantly higher cumulative number of exacerbations compared with the intermittently infected group by the end of both the second year (7 versus 4; $p=0.049$) and the third year (9.5 versus 6; $p=0.012$) after baseline.

TABLE 3 Baseline characteristics and outcomes of *Achromobacter xylosoxidans*-colonised patients with cystic fibrosis stratified by *Pseudomonas aeruginosa* co-isolation status

Characteristics or outcomes	Co-isolation status		p-value
	Ax+ Pa− (n=9)	Ax+ Pa+ (n=27)	
Baseline characteristics			
Female	5 (55.6)	14 (51.9%)	1.00
Homozygous F508del	3 (33.3)	11 (44.0)	0.70
Pancreatic insufficiency	6 (66.7)	24 (88.9)	0.15
Long-term azithromycin	3 (33.3)	11 (40.7)	1.00
MRSA isolation	1 (11.1)	7 (25.9)	0.65
Allergic bronchopulmonary aspergillosis	5 (55.6)	13 (48.1)	1.00
Age years	26.0 [21.0–36.0]	22.0 [20.0–28.0]	0.30
BMI kg·m ^{−2}	18.0 (17.7–20.8)	19.6 (17.7–21.6)	0.83
Suppressive antibiotherapy in the previous year	1 (11.1)	18 (66.7)	0.006
Intravenous antibiotherapy courses in the previous year	0.0 [0.0–2.0]	2.0 [1.0–4.0]	0.099
Outcomes			
Lung function			
ΔFEV ₁ %·year ^{−1}	−2.66±0.98	−6.05±0.54	0.003
ΔFEV ₁ mL·year ^{−1}	−105.4±32.77	−169.2±18.68	0.092
Number of exacerbations:			
Year before baseline, median (IQR)	2.0 (1.0–2.0)	3.0 (1.0–4.0)	0.11
Year after baseline, median (IQR)	2.0 (1.0–3.0)	3.0 (2.0–5.0)	0.037
Years 1 and 2 after baseline, median (IQR) [#]	5.0 [3.0–8.0]	6.5 [4.0–9.0]	0.26
Years 1–3 after baseline, median (IQR) [#]	8.0 (7.0–12.0)	9.0 (6.0–14.0)	0.40

Data are presented as n (%), median [interquartile range] or $\beta\pm\text{SE}$ [slope of change calculated from the baseline (time of bacterial detection)], unless otherwise stated. MRSA: methicillin-resistant *Staphylococcus aureus*; BMI: body mass index; FEV₁: forced expiratory volume in 1 s.[#]: cumulative number of exacerbations.

TABLE 4 Baseline characteristics and outcomes of patients with cystic fibrosis stratified by intermittent or chronic *Achromobacter xylosoxidans* isolation

Characteristics or outcomes	Intermittent (n=13)	Chronic (n=23)	p-value
Baseline characteristics			
Female	6 (46.2)	13 (56.5)	0.55
Age at <i>Achromobacter xylosoxidans</i> detection years	28.0 (26.0–36.0)	21.0 (19.0–28.0)	0.019
Weight kg	63.0 (47.0–67.0)	49.0 (44.0–56.0)	0.032
BMI kg·m ⁻²	21.1 (17.8–22.4)	18.7 (17.6–20.1)	0.052
Homozygous F508del	6 (46.2)	8 (38.1)	0.64
Pancreatic insufficiency	11 (84.6)	19 (82.6)	1.00
Diabetes	2 (15.4)	9 (39.1)	0.26
Azithromycin	2 (15.4)	12 (52.2)	0.030
<i>Pseudomonas aeruginosa</i> isolation	10 (76.9)	17 (73.9)	1.00
Allergic bronchopulmonary aspergillosis	6 (46.2)	12 (52.2)	0.73
FEV ₁ the year before <i>Achromobacter xylosoxidans</i> detection %	58.0 (30.0–75.0)	49.0 (31.0–77.0)	1.00
<i>Pseudomonas aeruginosa</i> antibiotic courses in year before baseline	2.0 (1.0–3.0)	3.0 (2.0–5.0)	NA
Outcomes			
Lung function			
ΔFEV ₁ %·year ⁻¹	−3.82±1.16	−5.55±0.52	0.17
ΔFEV ₁ mL·year ⁻¹	−135.9±38.56	−157.2±17.96	0.62
Number of exacerbations:			
Year before baseline	1.0 (1.0–3.0)	3.0 (2.0–4.0)	0.066
Year after baseline	2.0 (1.0–4.0)	3.0 (2.0–4.0)	0.22
Years 1 and 2 after baseline [#]	4.0 (3.0–6.0)	7.0 (5.0–9.0)	0.049
Years 1–3 after baseline [#]	6.0 (4.0–6.0)	9.5 (7.5–13.0)	0.012

Data are presented as n (%), median (interquartile range) or β±SE (slope of change calculated from the baseline (time of bacterial detection)), unless otherwise stated. BMI: body mass index; FEV₁: forced expiratory volume in 1 s. [#]: Cumulative number of exacerbations.

Discussion

Emerging evidence suggests that the lungs of patients with CF are colonised by a broader range of pathogens than previously recognised. The presence of *Achromobacter* spp. has been investigated in several cohorts of patients with CF, but the results have been controversial. Our study of French patients with CF makes several important points. First, *A. xylosoxidans*-colonised patients had a lower ventilatory function at baseline, a greater annual rate of decline in FEV₁, and an increased exacerbation frequency within the 3 years after *A. xylosoxidans* detection than did patients who remained Ax−. Second, patients with both *A. xylosoxidans* and *P. aeruginosa* had a greater rate of decline in FEV₁ and more exacerbations than patients without *P. aeruginosa* isolation. Finally, patients with chronic *A. xylosoxidans* isolation had more exacerbations from the second year after *A. xylosoxidans* detection compared with the intermittently colonised patients.

The prevalence of *A. xylosoxidans* in our cohort was 13.1%, which is higher than the 6.3% reported by the French Cystic Fibrosis Registry [1] but comparable to cohorts in studies performed in other European countries such as Spain [9] and Italy [7]. Although the risk factors for *A. xylosoxidans* isolation are unclear, advanced age and chronic *P. aeruginosa* isolation seem to be common among CF patients with chronic *A. xylosoxidans* infection [12, 13]. The baseline characteristics of our study cohort were typical according to the French Cystic Fibrosis Registry [1]; for example, 41.6% of our patients were homozygous for F508del, and 83.3% had exocrine pancreatic insufficiency. Similarly, with respect to potential genetic confounding factors, the proportion of patients in our Ax− cohort (13 out of 36, 36.1%) and Ax+ cohort (17 out of 36, 47.2%) were heterozygous for F508del, which are comparable to the national registry data (42%). The small inter-group difference in our study (four patients) is thus unlikely to have impacted the results. A higher proportion of the Ax+ cohort than the Ax− cohort in our study presented with allergic bronchopulmonary aspergillosis (50% versus 31%). While this difference was not statistically significant, a higher prevalence of allergic bronchopulmonary aspergillosis has also been noted in Ax+ compared with Ax− patients with CF in another case-control study [12].

In our study, Ax+ patients had worse lung function at baseline than matched Ax− patients, which is in agreement with previous studies [8, 14] and suggests that severe lung disease may be associated with increased susceptibility to *A. xylosoxidans* isolation. We also found that *A. xylosoxidans* infection was associated with a significantly greater decline in FEV₁ in the first 3 years after *A. xylosoxidans* detection. Some studies have reported that FEV₁ is the respiratory function parameter that best correlates with

mortality in patients with CF [15, 16]. In particular, the rate of FEV₁ decline seems to be a good predictor of prognosis for patients with CF [17]. Thus, our results could suggest that *A. xylosoxidans* isolation is a predictor of worse prognosis.

An association between decline in lung function and *A. xylosoxidans* isolation has also been observed in other studies of patients with CF. A recent Spanish study of 21 patients with CF found that the presence of *A. xylosoxidans* was associated with an increased decline in lung function parameters (FVC and FEV₁), and with more exacerbations [9]. Similarly, in a study of six French Ax+ patients and 11 matched controls, GODBERT *et al.* [12] showed that FEV₁ declined significantly faster and to a greater extent among the Ax+ patients compared with the controls. A study of 16 Ax+ and Ax− patients with CF in Denmark found the same trend in worsening respiratory function for Ax+ patients with high levels of anti-*A. xylosoxidans* antibodies [18]. In stark contrast, no significant differences in the rate of FEV₁ decline were reported by LAMBIASE *et al.* [7], who compared six *A. xylosoxidans*-colonised and six *P. aeruginosa*-colonised patients with CF, and by DE BAETS *et al.* [8], who compared 8 Ax+ with 16 Ax− patients with CF, and by TAN *et al.* [19] who compared 13 chronic *A. xylosoxidans*-colonised children with controls.

Our finding that *A. xylosoxidans* isolation significantly increased the cumulative number of exacerbations within 3 years of *A. xylosoxidans* detection underscores the potential importance of this pathogen for patient prognosis. Indeed, in a 5-year modelling study, the detrimental effect of each exacerbation was predicted to be equivalent to a 12% loss of FEV₁ [20]. These results are consistent with previous studies showing that *A. xylosoxidans*-colonised patients with CF had more hospitalisations and intravenous antibiotic treatment courses than matched Ax− patients (n=8 per group) [8]. The aforementioned case-control study by GODBERT *et al.* [12] also found an association between *A. xylosoxidans* isolation and more frequent hospitalisations and antibiotic courses. Nevertheless, one study has shown no link between *A. xylosoxidans* infection and pulmonary exacerbations. Among a cohort of 1103 Canadian patients with CF followed for 18 years, exacerbations were more frequent among the 48 patients with chronic *A. xylosoxidans* infection compared with those with intermittent or no history of infection, but this difference was not statistically significant after adjustment for potential confounders [21].

The majority (75%) of our 72-patient cohort was colonised with *P. aeruginosa*, and subgroup analysis revealed that the presence of *P. aeruginosa* was associated with a significantly greater annual decline in FEV₁. DIAMANTEA *et al.* [22] discovered a similar trend in their cohort of 11 Ax+ Pa+ and four Ax+ Pa− patients with CF. These findings indicate that isolation by *P. aeruginosa* is detrimental to the lung function of Ax+ patients with CF, although it should be noted that the extent of chronic lung inflammation, as measured by cytokine production, was found to be comparable in Ax+ patients and Pa+ patients with CF [23].

Our comparison of patients with intermittent *versus* chronic *A. xylosoxidans* isolation identified no effect on FEV₁, but the chronically infected patients did have significantly more exacerbations than the intermittently infected group in the 3 years after *A. xylosoxidans* identification (9.5 *versus* 6.0; p=0.012). The proportion of chronically *A. xylosoxidans*-colonised patients in our study (23 out of 36, 64%) was comparable to that in the aforementioned Spanish study, which found the same association between chronic *A. xylosoxidans* infection and frequency of exacerbations [9]. In a North American case-control study of 32 patients with CF, chronic *A. xylosoxidans* isolation was associated with significantly more intravenous antibiotic courses within an 18-month period, but not with a difference in FEV₁, compared with intermittently infected patients [24]. FIRMIDA *et al.* [25] also reported a trend towards lower FEV₁ in chronically *A. xylosoxidans*-infected compared with either intermittently *A. xylosoxidans*-infected patients or non-carriers, but the differences were not statistically significant. Similarly, a Canadian study of 34 *A. xylosoxidans*-colonised patients with CF found no significant differences between persistently infected (n=10) and intermittently infected (n=24) or matched control subjects (n=18) in either FEV₁ or number of exacerbations [24]. Finally, in a Belgian study, fewer than a third of the Ax+ cohort of CF patients was chronically colonised, and although this group exhibited an increased hospitalisation rate, their lung function decline was not significantly different from that of patients infected with *A. xylosoxidans* only once [26].

This study has several limitations. First, the retrospective observational nature of the analysis has well-known limitations. Second, the number of statistical tests performed was limited, and we cannot exclude that some differences between cohorts may have been missed. Missing data are another potentially confounding factor that cannot be ruled out, even in a case-matched study. Third, the sample size was small, with only 36 patients identified over the 7-year study period. Nevertheless, this study is relevant because isolation by *A. xylosoxidans* is a rare event among patients with CF. Moreover, previous studies have generally included even smaller patient numbers. Fourth, the monocentric nature of the recruitment hinders generalisation of the results, and additional multicentre studies on this subject are warranted.

Finally, we chose a time period of ± 4 years for age matching between *Ax+* and *Ax-* patients, which is a sufficiently large window that age-related differences in lung function may be a potential confounding factor [27]. Indeed, the *A. xylosoxidans*-colonised patients were significantly older than the *Ax-* patients in this study (23.5 versus 19.5 years; $p < 0.001$), which could be explained by the tendency for *A. xylosoxidans* isolation to occur at older ages. An age difference of similar magnitude was also seen in the aforementioned American study, in which the median age of transiently *A. xylosoxidans*-infected, chronically *A. xylosoxidans*-infected and control CF patients was 25, 24 and 22 years of age, respectively [24].

To conclude, this study provides further evidence that lung isolation by *A. xylosoxidans* in patients with CF has a detrimental effect on respiratory function, as reflected by a larger decline in FEV₁, a higher number of exacerbations, and an increased need for intravenous antibiotic courses compared with *Ax-* patients. Co-isolation with *P. aeruginosa* and chronic *A. xylosoxidans* isolation are also associated with increased severity of respiratory disease. These results highlight the need for clinicians to be vigilant in monitoring the presence of lung pathogens in CF patients, and suggest that the time may have come for standardised management strategies for the control, or even systematic eradication, of primary *A. xylosoxidans* infections, as currently recommended for *P. aeruginosa*.

Acknowledgements: The authors wish to thank Anne M. O'Rourke (O'Rourke Scientific and Medical Writing, San Diego, CA, USA) for editing a version of the manuscript.

Conflict of interest: M. Tetart has nothing to disclose. F. Wallet has nothing to disclose. M. Kyheng has nothing to disclose. S. Leroy has nothing to disclose. T. Perez reports being the principal investigator of a clinical study evaluating a device for chest clearance in cystic fibrosis (Simeox, PhysioAssist). O. Le Rouzic reports personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, and nonfinancial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, the Santelys Association, Vertex and Vitalaire, outside the submitted work. B. Wallaert reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. A. Prevotat reports personal fees from Vertex and GSK, and congress invitations from Teva and Novartis, outside the submitted work.

References

- 1 Bellis G, Dehillotte C, Lemonnier L, et al. French Cystic Fibrosis Registry - 2016 Data Review.
- 2 Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989; 245: 1066–1073.
- 3 Abbott IJ, Peleg AY. *Stenotrophomonas*, *Achromobacter*, and nonmeliod *Burkholderia* species: antimicrobial resistance and therapeutic strategies. *Semin Respir Crit Care Med* 2015; 36: 99–110.
- 4 Ratjen F, Döring G. Cystic fibrosis. *Lancet Lond Engl* 2003; 361: 681–689.
- 5 Yabuuchi E, Oyama A. *Achromobacter xylosoxidans* n. sp. from human ear discharge. *Jpn J Microbiol* 1971; 15: 477–481.
- 6 Kidd TJ, Ramsay KA, Hu H, et al. Low rates of *Pseudomonas aeruginosa* misidentification in isolates from cystic fibrosis patients. *J Clin Microbiol* 2009; 47: 1503–1509.
- 7 Lambiase A, Catania MR, del Pezzo M, et al. *Achromobacter xylosoxidans* respiratory tract infection in cystic fibrosis patients. *Eur J Clin Microbiol Infect Dis* 2011; 30: 973–980.
- 8 De Baets F, Schelstraete P, Van Daele S, et al. *Achromobacter xylosoxidans* in cystic fibrosis: prevalence and clinical relevance. *J Cyst Fibros* 2007; 6: 75–78.
- 9 Recio R, Branas P, Martinez MT, et al. Effect of respiratory *Achromobacter* spp infection on pulmonary function in patients with cystic fibrosis. *J Med Microbiol* 2018; 67: 952–956.
- 10 Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. *J Cyst Fibros Off J Eur Cyst Fibros Soc* 2014; 13: Suppl. 1, S23–S42.
- 11 Standardized lung function testing. Official statement of the European Respiratory Society. *Eur Respir J* 1993; 6: Suppl. 16, 1–100.
- 12 Godbert B, Briault A. Cystic fibrosis: *Achromobacter xylosoxidans* colonized patients have more severe respiratory disease. *Eur Respir J* 2013; 42: Suppl. 57, P1175.
- 13 Vongthilath R, Dehillotte C, Lemonnier L, et al. PYOnever study: adults patients with cystic fibrosis characteristics without lung *Pseudomonas aeruginosa* colonization. *Rev Mal Respir* 2017; 34: A33.
- 14 Hansen C R, Pressler T, Høiby N, et al. Chronic infection with *Achromobacter xylosoxidans* in cystic fibrosis patients; a retrospective case control study. *J Cyst Fibros* 2006; 5: 245–251.
- 15 Szczesniak R, Heltshe SL, Stanojevic S, et al. Use of FEV₁ in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher. *J Cyst Fibros* 2017; 16: 318–326.
- 16 Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. *N Engl J Med* 1992; 326: 1187–1191.
- 17 Que C, Cullinan P, Geddes D. Improving rate of decline of FEV₁ in young adults with cystic fibrosis. *Thorax* 2006; 61: 155–157.
- 18 Hansen CR, Pressler T, Høiby N, et al. Chronic infection with *Achromobacter xylosoxidans* in cystic fibrosis patients; a retrospective case control study. *J Cyst Fibros* 2006; 5: 245–251.
- 19 Tan K, Conway SP, Brownlee KG, et al. *Alcaligenes* infection in cystic fibrosis. *Pediatr Pulmonol* 2002; 34: 101–104.
- 20 Sanders DB, Bittner RCL, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. *Am J Respir Crit Care Med* 2010; 182: 627–632.
- 21 Somayaji R, Stanojevic S, Tullis DE, et al. Clinical outcomes associated with *Achromobacter* species infection in patients with cystic fibrosis. *Ann Am Thorac Soc* 2017; 14: 1412–1418.

- 22 Diamantea F, Petta V, Kotsifas K, *et al.* 57 *Achromobacter xylosoxidans* chronic infection and its clinical significance in a cohort of cystic fibrosis adult patients. *J Cyst Fibros* 2016; 15: S66.
- 23 Hansen CR, Pressler T, Nielsen KG, *et al.* Inflammation in *Achromobacter xylosoxidans* infected cystic fibrosis patients. *J Cyst Fibros* 2010; 9: 51–58.
- 24 Edwards BD, Greysson-Wong J, Somayaji R, *et al.* Prevalence and Outcomes of *Achromobacter* species infections in adults with cystic fibrosis: a North American cohort study. *J Clin Microbiol* 2017; 55: 2074–2085.
- 25 Firmida MC, Pereira RHV, Silva EASR, *et al.* Clinical impact of *Achromobacter xylosoxidans* colonization/infection in patients with cystic fibrosis. *Braz J Med Biol Res* 2016; 49: e5097.
- 26 Christiaens L, Goeminne P, Dupont L. *Achromobacter xylosoxidans*: friend or foe? *Eur Respir J* 2011; 38: Suppl. 55, 4292.
- 27 Kerem E, Viviani L, Zolin A, *et al.* Factors associated with FEV₁ decline in cystic fibrosis: analysis of the ECFS Patient Registry. *Eur Respir J* 2014; 43: 125–133.